Published in Cancer on October 15, 1980
Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Accuracy in clinically evaluating pigmented lesions. BMJ (1989) 1.44
Tumour spectrum in the FAMMM syndrome. Br J Cancer (1981) 1.24
Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count. Am J Epidemiol (2008) 1.21
Proposed alternative terminology and subclassification of so called "dysplastic naevi". J Clin Pathol (1986) 1.07
The dysplastic naevus. J Clin Pathol (1997) 1.02
Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome Ip36. Am J Hum Genet (1990) 1.00
Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev (2013) 0.98
Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol (2000) 0.97
Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn (2002) 0.92
Surgical prophylaxis of malignant melanoma. Ann Surg (1991) 0.88
Use of monoclonal antibodies in detection of melanoma-associated antigens in intact human tumors. Am J Pathol (1982) 0.87
Phenotypic variation in the familial atypical multiple mole-melanoma syndrome (FAMMM). J Med Genet (1983) 0.86
Relation between phenotype and banal melanocytic naevi. Br Med J (Clin Res Ed) (1987) 0.84
Melanoma risk factors and atypical moles. West J Med (1994) 0.83
Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol (1995) 0.82
The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi. Arch Dermatol Res (1990) 0.77
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
The mythical concept and untoward consequences of a diagnosis of dysplastic nevus: an overdue tribute to A. Bernard Ackerman, MD. Dermatol Pract Concept (2015) 0.75
Pigmentary Markers in Danes - Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome. PLoS One (2016) 0.75
A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both. J Med Genet (1984) 0.75
Changes of melanocytic lesions inducedby Melanotan injections and sun bed use ina teenage patient with FAMMM syndrome. Dermatol Pract Concept (2012) 0.75
Correlation between dermoscopic and histopathological diagnoses of atypical nevi in a dermatology outpatient clinic of the Medical School of São José do Rio Preto, SP, Brazil. An Bras Dermatol (2013) 0.75
Dermatology-important advances in clinical medicine: dysplastic nevus syndrome. West J Med (1983) 0.75
Familial dysplastic naevus syndrome. J R Soc Med (1988) 0.75
[Dysplastic melanocytic nevus]. Pathologe (2015) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
THE CLINICAL EVALUATION OF AUREOMYCIN. J Clin Invest (1949) 3.60
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol (1978) 2.81
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst (1998) 2.53
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet (2005) 2.13
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
The developmental biology of primary human malignant melanomas. Semin Oncol (1975) 1.92
Premarital sex, schoolgirl pregnancy, and school quality in rural Kenya. Stud Fam Plann (2001) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA (1978) 1.74
The dynamics of a heroin addiction epidemic. Science (1973) 1.74
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Amyl nitrite may alter T lymphocytes in homosexual men. Lancet (1982) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Incidence of Kaposi's sarcoma and mycosis fungoides in the United States including Puerto Rico, 1973-81. J Natl Cancer Inst (1984) 1.54
Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst (1978) 1.53
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Primary malignant melanoma of the urinary bladder. Cancer (1976) 1.48
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet (1986) 1.39
Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 1.38
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol (1986) 1.34
Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet (1986) 1.34
Malignant melanoma in renal-transplant recipients. Lancet (1981) 1.33
Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet (1982) 1.31
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med (1982) 1.29
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
A fine-structure study of the human epidermal melanosome complex and its acid phosphatase activity. J Ultrastruct Res (1968) 1.26
Familial and sporadic Hodgkin's disease associated with occupational wood exposure. Lancet (1978) 1.26
Radiogenic male breast cancer with in vitro sensitivity to ionizing radiation and bleomycin. Cancer Invest (1983) 1.24
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med (1986) 1.23
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol (1993) 1.23
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature (1987) 1.21
Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene (2007) 1.19
Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol (1979) 1.18
Progressive arterial occlusive disease (Köhlmeier-Degos). A frequently fatal cutaneosystemic disorder. N Engl J Med (1967) 1.17
Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res (1983) 1.17
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet (1984) 1.15
Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 1.14
Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol (1999) 1.13
A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13
Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet (1980) 1.12
Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med (1983) 1.12